Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Article on James Allison and Marker:

https://www.marketwatch.com/story/how-to-invest-in-biotech-stocks-like-a-nobel-prize-winner-2019-10-24

Highlights:
Everyone knows about mimicking the holdings of investment wizards, such as Warren Buffett and Carl Icahn, for stock ideas. Instead, I’d like to introduce you to someone who’s unknown: cancer-therapy researcher James Allison.

Why should you care what companies he’s in?

First, Allison is a rare genius in biotech. He helped invent an entire branch of cancer treatment called immunotherapy, and he won Nobel Prize for it in 2018. Second, coat-tailing is especially useful in biotech, which I will demonstrate in a moment. Third, Allison is one of the good guys in the world, so he’s not lending his name to companies just for a fast buck.

Market Therapeutics
Marker Therapeutics MRKR, +1.72% (formerly called TapImmune) has technology that grows rare cancer-killing T cells that recognize antigens on tumor cells. The company’s management thinks these T cells can be injected into the body to kill cancer cells. Marker is also developing an antigen-expression technology called PolyStart, which may help the immune system recognize and destroy diseased cells.

Note: Of the three small companies mentioned here, this is the one that has the best ownership profile, according to the system I use at my stock letter.

The Allison connection: He’s on the company’s scientific advisory board, along with Sharma at the MD Anderson Cancer Center.